| Previous Close | 7.6650 |
|---|---|
| Day's Range | 4.1101 - 6.5500 |
| 52 Week Range | 4.1100 - 69.5000 |
| Volume | 1,689,226 |
| Avg. Volume | 180,241 |
What is TherapeuticsMD's stock symbol?
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million. BOCA RATON, Fla., April 14, 2022--TherapeuticsMD, Inc. (NASDAQ: TXMD), ("TXMD" or the "Company") an innovative, leading women’s healthcare company, announced today the closing of the divestiture of vitaCare Prescription Services to …
Does TherapeuticsMD stock have a dividend growth track record?
Apr 17, 2022 · TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TXMD stock has decreased by 87.7% and is now trading at $0.1870. View which stocks have been most impacted by COVID-19.
What are analysts'target prices for TherapeuticsMD's shares?
May 10, 2022 · What's Happening with TXMD Stock Today TherapeuticsMD Inc (TXMD) stock is down -11.19% while the S&P 500 has gained 1.12% as of 1:50 PM on Tuesday, May 10. TXMD is lower by -$0.54 from the previous closing price of $4.84 on volume of 860,425 shares. Over the past year the S&P 500 is lower by -3.64% while TXMD is lower by -91.81%.
Should you worry about TherapeuticsMD stock?
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 8, 2022, the company approved non-statutory stock options to purchase an aggregate of …
Is Therapeutics MD a good stock to buy?
Is TXMD a good buy right now?
The 2 analysts offering 12-month price forecasts for TherapeuticsMD Inc have a median target of 1.75, with a high estimate of 2.50 and a low estimate of 1.00. The median estimate represents a +1,041.55% increase from the last price of 0.15.
Does TXMD have a future?
Why is TXMD dropping?
Will CEI stock go up?
How high does IDEX go?
The 2 analysts offering 12-month price forecasts for Ideanomics Inc have a median target of 2.00, with a high estimate of 3.00 and a low estimate of 1.00. The median estimate represents a +213.23% increase from the last price of 0.64.
Is ship stock a buy?
Who owns TherapeuticsMD?
What is the future of Tilray stock?
The 15 analysts offering 12-month price forecasts for Tilray Brands Inc have a median target of 7.25, with a high estimate of 23.00 and a low estimate of 4.50. The median estimate represents a +65.15% increase from the last price of 4.39.
What happens when a stock is delisted?
Is TXMD shorted?
This table shows the number of shares of US:TXMD available to be shorted at a leading prime brokerage.
What is TXMD working on?
Is TherapeuticsMD a buy right now?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 buy ratings for the...
How has TherapeuticsMD's stock price been impacted by Coronavirus (COVID-19)?
TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health O...
When is TherapeuticsMD's next earnings date?
TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022. View our earnings forecast for Therapeu...
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD, Inc. (NASDAQ:TXMD) released its earnings results on Thursday, March, 10th. The company reported ($0.10) EPS for the quarter, missin...
What price target have analysts set for TXMD?
2 equities research analysts have issued 1 year price targets for TherapeuticsMD's shares. Their forecasts range from $2.50 to $5.00. On average, t...
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the following people: Hugh O'Dowd , President, Chief Executive Officer & Director James C. Darecca , C...
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include Cara Therapeutics (CARA) , Collegium Pharmaceutical (COLL) , Eagle Pharmaceuticals (EG...
What other stocks do shareholders of TherapeuticsMD own?
Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK) ,...
What is TherapeuticsMD's stock symbol?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
Recently Viewed Tickers
Visit a quote page and your recently viewed tickers will be displayed here.
TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 0.00% and 1.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD Announces Second Quarter 2021 Financial Results
BOCA RATON, Fla., August 04, 2021--TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the second quarter ended June 30, 2021.
Will TherapeuticsMD (TXMD) Report Negative Earnings Next Week? What You Should Know
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021
BOCA RATON, Fla., July 26, 2021--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 4, 2021, before the opening of the U.S. financial markets.
Breakeven On The Horizon For TherapeuticsMD, Inc. (NASDAQ:TXMD)
TherapeuticsMD, Inc. ( NASDAQ:TXMD ) is possibly approaching a major achievement in its business, so we would like to...
Is TherapeuticsMD a buy right now?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TherapeuticsMD stock.#N#View analyst ratings for TherapeuticsMD or view top-rated stocks.
What stocks does MarketBeat like better than TherapeuticsMD?
Wall Street analysts have given TherapeuticsMD a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TherapeuticsMD wasn't one of them.
Are investors shorting TherapeuticsMD?
TherapeuticsMD saw a drop in short interest in the month of August. As of August 13th, there was short interest totaling 22,580,000 shares, a drop of 30.2% from the July 29th total of 32,340,000 shares. Based on an average daily volume of 5,620,000 shares, the days-to-cover ratio is currently 4.0 days.#N#View TherapeuticsMD's Short Interest.
When is TherapeuticsMD's next earnings date?
TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.#N#View our earnings forecast for TherapeuticsMD.
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD, Inc. (NASDAQ:TXMD) posted its quarterly earnings results on Wednesday, August, 4th. The company reported ($0.11) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.11).
How has TherapeuticsMD's stock been impacted by Coronavirus (COVID-19)?
TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TXMD stock has decreased by 49.3% and is now trading at $0.77.#N#View which stocks have been most impacted by COVID-19.
What price target have analysts set for TXMD?
3 brokers have issued twelve-month target prices for TherapeuticsMD's shares. Their forecasts range from $4.00 to $5.00. On average, they expect TherapeuticsMD's stock price to reach $4.50 in the next year.
PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three recipients who will receive funding through the company's STRIVE Awards program. The global STRIVE Awards program provides grants to non-profit organizations serving the Duchenne muscular dystrophy community.
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences:
PTC Therapeutics' Waylivra Scores Approval In Brazil For Genetic Disorder
The Brazilian Health Regulatory Agency has approved PTC Therapeutics Inc's (NASDAQ: PTCT) Waylivra (volanesorsen) as the first treatment for familial chylomicronemia syndrome (FCS). The approval is based on the Phase 3 APPROACH study results and the APPROACH Open-Label Extension study and is supported by results from the Phase 3 COMPASS study.
Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of a manuscript, "Gene Therapy in the Putamen for Curing AADC Deficiency and Parkinson's Disease," in the European Molecular Biology Organization Journal.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Aug. 17, 2021, it approved non-statutory stock options to purchase an aggregate of 51,670 shares of its common stock and 19,755 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 48 new employees.
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2021.
PTC Therapeutics (PTCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Verve Therapeutics a buy right now?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock.
What stocks does MarketBeat like better than Verve Therapeutics?
Wall Street analysts have given Verve Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Verve Therapeutics wasn't one of them.
When is Verve Therapeutics' next earnings date?
Verve Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.#N#View our earnings forecast for Verve Therapeutics.
How were Verve Therapeutics' earnings last quarter?
Verve Therapeutics, Inc. (NASDAQ:VERV) released its quarterly earnings results on Thursday, August, 12th. The company reported ($2.13) EPS for the quarter, missing the consensus estimate of ($0.53) by $1.60.#N#View Verve Therapeutics' earnings history.
What price target have analysts set for VERV?
4 Wall Street analysts have issued 12-month price targets for Verve Therapeutics' shares. Their forecasts range from $50.00 to $92.00. On average, they expect Verve Therapeutics' stock price to reach $74.50 in the next twelve months.
Who are some of Verve Therapeutics' key competitors?
Some companies that are related to Verve Therapeutics include CureVac (CVAC), Ono Pharmaceutical (OPHLF), Dr.
What is Verve Therapeutics' stock symbol?
Verve Therapeutics trades on the NASDAQ under the ticker symbol "VERV."
What is TherapeuticsMD stock?
TherapeuticsMD ( NASDAQ:TXMD) is a small-cap pharmaceutical stock that focuses on women's health issues. The company is still in its early growth stages, but with three products already in its portfolio, it could be an attractive growth opportunity for investors today.
Who is David Jagielski?
David Jagielski is a designated accountant and has spent 10+ years working in finance for small and large businesses in many different sectors. He has been writing for The Fool since 2017. When he's not out hunting for cheap stocks or writing articles, odds are he's writing macros in Excel or reading history books. Follow @davidjagielski.
